This page shows the latest inhaled insulin news and features for those working in and with pharma, biotech and healthcare.
Sanofi has handed back rights to inhaled insulin drug Afrezza to Mannkind, less than a year after its launch, after the diabetes treatment saw underwhelming sales. ... The disappointing performance of the drug also promoted other inhaled insulin
oral and inhaled insulin. ... I think the jury is out on inhaled insulin,” he says.
As Viehbacher's replacement Brandicourt faces a number of challenges, including the impending loss of patent protection for Sanofi big-selling diabetes therapy Lantus (insulin glargine). . ... The company also has a number of key product launches
Partners with MannKind on only diabetes treatment of its kind. . The device Afrezza will be distributed in. Sanofi has launched what will be the only inhaled insulin available to treat people ... Afrezza is the only product of its kind available in the
French company bolsters diabetes business with Afrezza collaboration. This inhaler is designed to be used with Mannkind's inhaled insulin Afrezza. ... MannKind's search for a partner for its recently approved inhaled insulin therapy Afrezza has ended
US FDA backs new diabetes treatment Afrezza. An inhaled formulation of insulin for diabetes could be back on the market shortly after the US FDA approved MannKind's Affrezza. ... Afrezza is a short-acting inhaled insulin, a group which represents around
More from news
Approximately 4 fully matching, plus 31 partially matching documents found.
It was a big news month for Sanofi, also in the news for terminating its licensing deal with MannKind for Afrezza (inhaled insulin). ... 150. MannKind/ Receptor Life Sciences. Licence, collaboration. Multiple inhaled therapeutic products for conditions
The only alternative to injections of the hormone at the moment is Mannkind's inhaled insulin Afrezza - partnered with Sanofi - which has not gained much momentum yet in the marketplace with ... like peptide-1 (GLP-1), a hormone that works independently
The first of these came in February with the debut of Afrezza, the only inhaled insulin available in the US. ... The drug-device combination delivers a dry formulation of human insulin via a small and portable inhaler, similar to those associated with
8, 300. MannKind/ Sanofi. Licence. Afrezza (human insulin) Rapid-Acting Inhaled Insulin (approved US).
the leading pack diabetes drug companies, to ignore any lurking concerns caused by Pfizer's woeful experience with inhaled insulin (Exubera) and jump into this precarious game with MannKind. . ... The drug-device combination consists of a dry
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...